United Therapeutics Co. (NASDAQ:UTHR) Holdings Decreased by Amalgamated Bank

Amalgamated Bank cut its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 29,025 shares of the biotechnology company’s stock after selling 820 shares during the period. Amalgamated Bank’s holdings in United Therapeutics were worth $6,382,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC acquired a new position in United Therapeutics in the fourth quarter valued at approximately $43,000. C M Bidwell & Associates Ltd. bought a new stake in shares of United Therapeutics in the 3rd quarter worth approximately $91,000. Blue Trust Inc. grew its stake in United Therapeutics by 10.0% during the 4th quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock worth $114,000 after buying an additional 46 shares during the last quarter. CWM LLC lifted its stake in United Therapeutics by 45.7% in the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company’s stock valued at $147,000 after buying an additional 210 shares during the last quarter. Finally, Synovus Financial Corp acquired a new position in shares of United Therapeutics during the third quarter valued at $203,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 11th. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday. SVB Leerink started coverage on shares of United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 target price on the stock. Finally, Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $308.78.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,880,130.69. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,756.70. The disclosure for this sale can be found here. Insiders sold 141,790 shares of company stock valued at $33,572,685 in the last three months. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Trading Up 1.7 %

NASDAQ:UTHR opened at $262.40 on Monday. The stock’s 50-day moving average is $236.86 and its two-hundred day moving average is $229.35. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The stock has a market cap of $11.64 billion, a PE ratio of 12.41 and a beta of 0.54. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $262.51.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the prior year, the firm earned $4.86 EPS. The company’s revenue was up 33.7% compared to the same quarter last year. As a group, equities research analysts forecast that United Therapeutics Co. will post 23.88 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.